# Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

Source: https://onco.cc/trials/nct07232290/  
OnCo record `nct07232290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Flonoltinib 75mg in myeloproliferative neoplasms, run by Chengdu Zenitar Biomedical Technology Co., Ltd, now recruiting.

## Summary

Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera is a phase 2 interventional study registered as NCT07232290 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 60 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-07-30. Interventions recorded: Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg and Extended Phase Dose Group.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07232290
- Phase: 2
- Setting: An Open Label, Randomized, Parallel Controlled, Multicenter Phase IIa Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Flonoltinib Maleate Tablets in the Treatment of Hydroxyurea or Interferon Resistant/Intolerant Polycythemia Vera
- Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07232290: https://clinicaltrials.gov/study/NCT07232290

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- companies: [Chengdu Zenitar Biomedical Technology](https://onco.cc/companies/chengdu-zenitar-biomedical-technology/)
- drugs: [Flonoltinib](https://onco.cc/drugs/flonoltinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07232290.json